Novavax’s 2024-2025 COVID-19 Vaccine Receives EUA for Use in the U.S.
Novavax, Inc. (Nasdaq: NVAX), a leading company in protein-based vaccines, has announced that its latest COVID-19 vaccine, the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This authorization permits its use for active immunization to prevent COVID-19 in individuals aged 12 and […]